Aviptadil

At a glance

Overview

VIP occurs naturally in the nervous system, gut, lungs, and other tissues. Its vasodilatory and immunologic actions prompted study of aviptadil in acute respiratory disease, including COVID-19. Early hypotheses and small reports attracted attention, but larger controlled outcomes must guide interpretation. The TESICO trial did not show a significant clinical benefit from intravenous aviptadil in severe COVID-associated respiratory failure. Separately, Invicorp combines aviptadil with phentolamine for erectile dysfunction in certain European markets. This demonstrates why a molecule cannot be assigned one global approval status without specifying the product, route, combination partner, jurisdiction, and intended condition.

Supporting sources [1] [2] [3] [4]

How it works

VIP signaling through VPAC-family receptors increases intracellular cyclic AMP and can relax smooth muscle and modify inflammatory-cell responses. These effects supplied a rationale for protecting alveolar tissue and altering pulmonary inflammation. Vascular relaxation also creates potential for hypotension. In erectile-dysfunction treatment, the combination with an alpha-adrenergic blocker acts locally on penile blood flow; that established product context does not validate systemic treatment of lung inflammation.

Supporting sources [1] [2] [3] [4]

What TESICO found

The randomized TESICO study compared intravenous aviptadil with placebo in patients with COVID-19-associated acute hypoxemic respiratory failure. It found no significant improvement in the primary clinical outcome through day 90 and no demonstrated mortality benefit. Mechanistic plausibility and favorable subgroup narratives should not replace this overall controlled result.

Supporting sources [1]

The erectile-dysfunction product is separate

Invicorp contains aviptadil plus phentolamine and is used locally for erectile dysfunction in specified European settings. Regulatory product information describes this combination and its indication. That authorization is not an approval of aviptadil alone for ARDS, COVID-19, long COVID, or general immune enhancement in the United States.

Supporting sources [2]

Route and setting change the safety assessment

Systemic VIP activity can affect blood pressure and gastrointestinal function; aviptadil trials required close monitoring in critically ill patients. Local erectile-dysfunction therapy has a different adverse-effect context, including prolonged erection risk for the combination. Safety observations should not be moved between these routes without explaining the exposure and population differences.

Supporting sources [1] [2]

Does anti-inflammatory biology mean it treats lung injury?

No. Laboratory mechanisms identify a hypothesis, while clinical trials determine whether the intervention improves patient outcomes. VIP’s broad biological activity makes it scientifically interesting, but the respiratory trial illustrates that target-related effects can occur without a clinically useful net benefit.

Supporting sources [1] [3]